Medication and Treatment Response in HPHA

Because Hemiparkinsonism-Hemiatrophy Syndrome (HPHA) is so rare, there are no “standard” clinical practice guidelines or universal drug algorithms ^[1][2]. In most cases, doctors borrow treatments from typical Parkinson’s disease, but the results are much more unpredictable. Your treatment plan will likely be a process of supervised trial and observation to see which symptoms respond and which do not.

The primary goal of medication in HPHA is symptomatic: to manage the movement-related symptoms—slowness (bradykinesia), stiffness (rigidity), and tremor—to help you maintain your daily activities ^[3].

The Levodopa Trial

The most common first-line treatment is levodopa (often combined with carbidopa). This medication is converted to dopamine in the brain. However, in HPHA, the response to this drug is famously variable:

• Good Responders: Some patients experience a significant improvement in their stiffness and slowness, similar to what is seen in typical Parkinson’s disease ^[3][4].
• Poor Responders: Other patients find that levodopa has little to no effect on their symptoms ^[2]. A lack of response does not prove that symptoms are solely caused by muscle wasting or a fixed lesion; dose, duration, adherence, and the symptom being measured all matter.
• Supervised Adjustments: Any levodopa trial or dose adjustment must be supervised and symptom-based. Do not keep escalating the dose independently hoping a response will appear.

Other Medication Options

If levodopa alone isn’t enough, your doctor might discuss other classes of drugs, though evidence is very limited:

• Dopamine Agonists: These drugs mimic the effects of dopamine. While one documented case reported additional relief from adding a dopamine agonist ^[4], this is not evidence for routine use. Dopamine agonists carry severe potential side effects, including sudden sleep attacks, excessive daytime sleepiness, hallucinations, confusion, orthostatic hypotension (blood pressure drops), and impulse-control disorders (compulsive behaviors).
• Adjunctive Therapies: Doctors may use other Parkinson’s medications based on your specific symptoms, although there is very little research on how these perform in HPHA ^[1].

Managing Side Effects and Safety

Any medication that influences dopamine levels carries a risk of side effects.

• Dyskinesia: These are involuntary, “fidgety,” or “wiggly” movements that can occur during levodopa treatment ^[1]. It may be linked to how long you have had the condition or your medication dose.
• Safety Warning: Never change your dose or stop your medication abruptly without consulting your prescriber, as this can cause severe and potentially dangerous withdrawal effects. Contact your prescriber promptly if you experience hallucinations, severe sleepiness, fainting, compulsive behavior, troublesome involuntary movements, or abrupt loss of benefit.

Active Observation (“Wait and See”)

In some cases where symptoms are mild, patients and doctors choose to delay starting medication ^[1]. However, observation should be an active plan with a review interval and clear triggers for earlier reassessment, such as falls, worsening gait, swallowing problems, disabling stiffness, medication adverse effects, or mood/cognitive changes.

Ultimately, because HPHA involves both movement slowness and physical wasting, medication is symptomatic and is only one piece of the puzzle. It is most effective when combined with individualized rehabilitation ^[2].